Featured Research

from universities, journals, and other organizations

Promising Target For New Atherosclerosis Therapies Linked To Leukemia

Date:
November 2, 2006
Source:
The Wistar Institute
Summary:
In recent years, scientists studying inflammation and atherosclerosis have seen their respective fields converging, with research findings showing chronic inflammation as a driver of the atherosclerotic process. Now, in a new study, scientists at the Wistar Institute pursuing a promising new immune-system target for anti-atherosclerosis therapies have discovered another convergence: An unwanted potential side effect of any such therapies is a dangerous blood cancer called chronic myelogenous leukemia, or CML.

In recent years, scientists studying inflammation and atherosclerosis have seen their respective fields converging. Inflammation is an aspect of the immune response to injury and disease; atherosclerosis, with its characteristic lesions in the blood vessel walls, underlies most cardiovascular disease, including heart attacks and strokes.

Now, in a new study, scientists at The Wistar Institute pursuing a promising new immune-system target for anti-atherosclerosis therapies have discovered another convergence: An unwanted potential side effect of any such therapies is a dangerous blood cancer called chronic myelogenous leukemia, or CML. More positively, the CML seen in the genetic strain of mice used in the study closely mimics human CML, so that the mice offer a new model for studying CML, opening the door for researchers to better understand that disease. The Wistar team's results are featured on the cover of the current issue of the Journal of Experimental Medicine, published October 30.

The Wistar scientists initiated their experiments to build on a series of findings that had suggested that blocking certain enzymes called lipoxygenases could inhibit the kind of chronic inflammation in the blood vessel walls that drives the atherosclerotic process. Even better, blocking these enzymes seemed only to affect one type of immune cell, the macrophage, and to interfere only with its role in chronic inflammation. The acute response of the macrophages to infectious agents like bacteria, critical for protection against disease, remained unfettered.

"We and others had hoped that blocking this enzyme would safely slow or stop certain chronic inflammatory responses that have been linked to atherosclerosis," says Ellen Puré, Ph.D., a professor in the Molecular and Cellular Oncogenesis and Immunology programs at Wistar and senior author on the study. "Now we know that if we go that route, we may also unwittingly be promoting leukemia."

To better understand the details of this inflammatory process as it unfolds in atherosclerosis, the Wistar researchers worked with a strain of experimental mice lacking the gene for a specific pivotal lipoxygenase enzyme. They then crossed these mice with other strains of mice genetically prone to atherosclerosis. Would the resulting mice without the lipoxygenase enzyme be protected from developing atherosclerosis, or would their genetic susceptibility to atherosclerosis win out? Either way, precisely what mechanisms were at work in the vessel walls?

Focused as they were on the atherosclerotic process in the blood vessel walls, the researchers nearly overlooked a significant change taking place in another part of the body: To their surprise, they noticed that the spleens of the mice lacking lipoxygenase became enlarged, dramatically so in some cases. In 15 percent of the mice, the spleens grew 5 to 10 times their normal size at the end of a year.

"As immunologists, we couldn't ignore this," Puré says. "The spleen is an important organ of the immune system."

Exploring their observation, the scientists ascertained that the spleens of all of the mice in the experiments were somewhat enlarged, swollen with cells called granulocytes and macrophages, members of a family of immune cells called myeloid cells. The majority of mice were seen to have myeloid proliferative disease, a precursor to CML. And 15 percent of the mice had full-blown leukemias.

"The enzyme we were looking at is expressed in the progenitor cells in the bone marrow that give rise to all the different types of cells in one branch of the immune system," Puré notes. "So perhaps we shouldn't have been shocked to see that it had an effect on these cells to remove the enzyme from the system."

The silver lining in the situation, Puré says, is that the strain of mice used in their study may be the best model for human CML yet found. The subset of the mice with myeloid proliferative disease closely mimic the asymptomatic early stages of CML, while the 15 percent with clear CML model the crisis, or "blast," stage of the disease.

The lead author on the study is Melissa Kristine Middleton at Wistar. Alicia Marie Zukas, Tanya Rubinstein, Michele Jacob, Ph.D., and Liang Zhao, Ph.D., at Wistar are co-authors, as are Peijuan Zhu and Ian Blair at the University of Pennsylvania. Wistar professor Ellen Puré, Ph.D., is senior author; Puré also has affiliations with Penn and with The Ludwig Institute for Cancer Research.

Funding for the research was provided by the National Institutes of Health and the Commonwealth Universal Research Enhancement Program of the Pennsylvania Department of Health.


Story Source:

The above story is based on materials provided by The Wistar Institute. Note: Materials may be edited for content and length.


Cite This Page:

The Wistar Institute. "Promising Target For New Atherosclerosis Therapies Linked To Leukemia." ScienceDaily. ScienceDaily, 2 November 2006. <www.sciencedaily.com/releases/2006/11/061102092353.htm>.
The Wistar Institute. (2006, November 2). Promising Target For New Atherosclerosis Therapies Linked To Leukemia. ScienceDaily. Retrieved August 20, 2014 from www.sciencedaily.com/releases/2006/11/061102092353.htm
The Wistar Institute. "Promising Target For New Atherosclerosis Therapies Linked To Leukemia." ScienceDaily. www.sciencedaily.com/releases/2006/11/061102092353.htm (accessed August 20, 2014).

Share This




More Health & Medicine News

Wednesday, August 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Possible Ebola Patient in Isolation at California Hospital

Possible Ebola Patient in Isolation at California Hospital

Reuters - US Online Video (Aug. 20, 2014) — A patient who may have been exposed to the Ebola virus is in isolation at the Kaiser Permanente South Sacramento Medical Center. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Raw: World's Oldest Man Lives in Japan

Raw: World's Oldest Man Lives in Japan

AP (Aug. 20, 2014) — A 111-year-old Japanese was certified as the world's oldest man by Guinness World Records on Wednesday. Sakari Momoi, a native of Fukushima in northern Japan, was given a certificate at a hospital in Tokyo. (Aug. 20) Video provided by AP
Powered by NewsLook.com
Do More Wedding Guests Make A Happier Marriage?

Do More Wedding Guests Make A Happier Marriage?

Newsy (Aug. 20, 2014) — A new study found couples who had at least 150 guests at their weddings were more likely to report being happy in their marriages. Video provided by Newsy
Powered by NewsLook.com
Ebola-Hit Sierra Leone's Freetown a City on Edge

Ebola-Hit Sierra Leone's Freetown a City on Edge

AFP (Aug. 19, 2014) — Residents of Sierra Leone's capital voice their fears as the Ebola virus sweeps through west Africa. Duration: 00:56 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins